[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Centre hospitalier de l'Université de Montréal (CHUM)\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":635},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,98,0,25,[9,40,67,94,117,136,164,192,217,238,264,290,312,331,351,388,414,445,463,498,523,542,564,584,609],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":4},"100652744","development-and-validation-of-a-circulating-tumour-dna-marker-for-pre-neoplastic-colorectal-tumours-100652744",false,"NCT07776548","Development and Validation of a Circulating Tumour DNA Marker for Pre-neoplastic Colorectal Tumours.","ctDNA-LST","Inclusion Criteria:\n\n* Age ≥ 18 years.\n* Referred for resection of a large (≥ 10 mm) colorectal laterally spreading tumour (LST).\n* Lesion judged amenable to endoscopic resection by the treating endoscopist.\n* Able to provide written informed consent.\n\nExclusion Criteria:\n\n* Known concurrent or prior colorectal cancer, or another active malignancy that could contribute circulating tumour DNA.\n* Lesion \\\u003C 10 mm.\n* Inability to provide informed consent.","ALL","18 Years",{"count":20,"type":21},110,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this prospective interventional biomarker development and validation study is to determine whether circulating tumour DNA (ctDNA) can be detected in patients with large pre-neoplastic colorectal lesions undergoing endoscopic resection and whether ctDNA can be used to identify local recurrence after resection.\n\nThe main questions it aims to answer are:\n\n* Can advanced colorectal laterally spreading tumours (LSTs) shed detectable ctDNA into the bloodstream before endoscopic resection?\n* Can ctDNA measured at the first surveillance colonoscopy detect or predict local recurrence after endoscopic resection?\n\nParticipants will:\n\n* Provide a blood sample before their planned endoscopic resection procedure for ctDNA analysis.\n* Undergo standard endoscopic resection of their colorectal lesion.\n* Allow collection and molecular analysis of tissue samples obtained from the resected lesion.\n* Allow researchers to collect clinical, endoscopic, pathological, and molecular data from their medical records for research purposes.\n\nThe study does not alter the standard clinical management, resection technique, or surveillance schedule. The only study-specific procedures are blood sample collections performed during routine intravenous catheter placement for the participant's endoscopic procedures.",[27],"Advanced Colorectal Laterally Spreading Tumours (LSTs)","NOT_YET_RECRUITING","2026-08-17",{"date":31,"type":32},"2026-08-20","ACTUAL",{"date":34,"type":21},"2027-01-04",{"date":36,"type":21},"2029-01-03",{"name":38,"class":39},"Centre hospitalier de l'Université de Montréal (CHUM)","OTHER",{"id":41,"slug":42,"hasResults":12,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":46,"eligibilityCriteria":47,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":48,"targetDuration":4,"studyType":22,"phases":50,"briefSummary":51,"conditions":52,"keywords":56,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":4},"100535845","comparing-radiotherapy-immobilization-systems-for-anxious-hnc-patients-100535845","NCT06257121","Comparing Radiotherapy Immobilization Systems for Anxious HNC Patients","A Pilot Study to Assess the Use of Surface-guided Radiotherapy in Head and Neck Cancer Patients Who Suffer From Anxiety","CRISP","Inclusion Criteria:\n\n* Eighteen years of age or older\n* Able to fluently speak, read and write French or English\n* Histologically confirmed head and neck cancer\n* Patients treated with radiotherapy as primary treatment\n* Identified as having moderate mask anxiety \u002F claustrophobia (i.e. a score of 10 or more on the Generalized Anxiety Disorder 7 item (GAD-7) questionnaire and \u002F or a score of 28 or more on the Claustrophobia questionnaire (CLQ) suffocation subscale and \u002F a score of 24 or more on the CLQ restriction subscale\n* An Eastern Cooperative Oncology Group (ECOG) Performance Status grade of 0-2\n* Able to understand and sign consent form\n* Patients must be willing to comply with treatment plan and other study procedures\n\nExclusion Criteria:\n\n* Patients with significantly altered mental status or with psychological, familial, sociological or geographical condition potentially hampering compliance with the study\n* Patients who cannot stay still during fraction because of a disorder or physical condition (e.g., Parkinson's disease)",{"count":49,"type":21},15,[24],"Background: Radiotherapy is a mainstay of treatment for ENT cancers, and its indication is frequent. Patients are positioned and immobilized using a thermoplastic mask, which is attached to the treatment table for the duration of each daily treatment. The mask's purpose is to prevent patient movement and ensure reproducible positioning. The advantages of using thermoplastic masks come at a cost for many patients. It is well established that mask fixation and mask anxiety are major concerns for patients, adversely affecting their quality of life and hindering treatment compliance. Surface-guided radiotherapy (SGRT) enables patients to be positioned and their movements monitored in real time during treatment. This technique has become more widely available in recent years, and is attractive because it does not involve ionizing radiation. However, although preliminary data have suggested a potential reduction in anxiety, this technique has not been evaluated for ENT RT in anxious\u002Fclaustrophobic patients who cannot tolerate immobilization masks.\n\nObjective: Investigators propose a pilot study to evaluate the feasibility and tolerability of using SGRT to manage position for patients with ENT cancer who report claustrophobia\u002Fanxiety.\n\nMethodology: 15 participants will be recruited by the treating radiation oncologist from among patients scheduled to undergo radiation therapy at CHUM for their ENT cancer and identifying as claustrophobic\u002Fanxious. Participants who consent will be scheduled to undergo their radiotherapy using SGRT. Patients will be systematically treated with Volumetric Modulated Arc Therapy (VMAT) using SGRT on the linear accelerator with the Optical Surface Management System (OSMS) for the duration of the radiotherapy.\n\nMeasures: Patients' anxiety will be assessed using the GAD-7 and the CLQ throughout the treatment process. The feasibility and accuracy of radiotherapy treatment will be assessed using planning and daily pre-treatment examinations. In addition, skin toxicity will be assessed weekly.\n\nAnalyses: 1) Descriptive analyses, i.e. frequencies for categorical variables and means and standard deviations for continuous variables. 2) Estimation of confidence intervals.\n\nAnticipated outcomes: Completion of this pilot project will enable investigators to plan and refine the methodological and organizational aspects for a large-scale study, i.e., a Phase III clinical trial comparing the use of SGRT with the use of a thermoplastic immobilization mask for anxious patients.",[53,54,55],"Head and Neck Cancer","Claustrophobia","Anxiety",[57,55,54,58,59],"Head and neck cancer","Surface-guided imagery","Radiation therapy",{"date":61,"type":32},"2026-08-19",{"date":63,"type":21},"2026-10-15",{"date":65,"type":21},"2029-02-01",{"name":38,"class":39},{"id":68,"slug":69,"hasResults":12,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":73,"eligibilityCriteria":74,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":75,"targetDuration":4,"studyType":22,"phases":77,"briefSummary":78,"conditions":79,"keywords":4,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":93},"100538848","open-lung-protective-extubation-following-general-anesthesia-100538848","NCT06296173","Open Lung Protective Extubation Following General Anesthesia","Open Lung Protective Extubation Following General Anesthesia: the OLEXT-3 Trial","OLEXT-3","Inclusion Criteria:\n\n* Adult patients (18 years of age or over)\n* Elective intra-abdominal surgery under general anesthesia.\n* Moderate or high risk of postoperative pulmonary complication according to the ARISCAT score (score of 26 or more)\n* Planned postoperative hospitalization\n\nExclusion Criteria:\n\n* Expected or known difficult intubation according to the treating anesthesiologist\n* Postoperative mechanical ventilation (planned or unplanned)\n* General anesthesia performed outside the main operating room",{"count":76,"type":21},270,[24],"Perioperative respiratory complications are a major source of morbidity and mortality. Postoperative atelectasis plays a central role in their development. Protective \"open lung\" mechanical ventilation aims to minimize the occurrence of atelectasis during the perioperative period. Randomized controlled studies have been performed comparing various \"open lung\" ventilation protocols, but these studies report varying and conflicting effects. The interpretation of these studies is complicated by the absence of imagery supporting the pulmonary impact associated with the use of different ventilation strategies. Imaging studies suggest that the gain in pulmonary gas content in \"open lung\" ventilation regimens disappears within minutes after the extubation. Thus, the potential benefits of open-lung ventilation appear to be lost if, at the time of extubation, no measures are used to keep the lungs well aerated. Recent expert recommendations on good mechanical ventilation practices in the operating room conclude that there is actually no quality study on extubation.\n\nExtubation is a very common practice for anesthesiologists as part of their daily clinical practice. It is therefore imperative to generate evidence on good clinical practice during anesthetic emergence in order to potentially identify an effective extubation strategy to reduce postoperative pulmonary complications.",[80,81,82,83,84],"Intra-abdominal Surgery","Anesthesia","Lung Injury","Ventilator-Induced Lung Injury","Atelectasis","RECRUITING","2026-08-14",{"date":29,"type":32},{"date":89,"type":32},"2024-10-08",{"date":91,"type":21},"2027-04-01",{"name":38,"class":39},5,{"id":95,"slug":96,"hasResults":12,"nctId":97,"briefTitle":98,"officialTitle":98,"acronym":99,"eligibilityCriteria":100,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":101,"targetDuration":4,"studyType":103,"phases":4,"briefSummary":104,"conditions":105,"keywords":4,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":109,"startDateStruct":111,"completionDateStruct":113,"leadSponsor":115,"locationsCount":116},"100652171","lesion-size-measurement-during-gastrointestinal-endoscopies-100652171","NCT07770425","Lesion Size Measurement During Gastrointestinal Endoscopies","AccuMeasure","Inclusion Criteria:\n\n* Adult patients (18 years and older)\n* Patients undergoing gastrointestinal endoscopy procedures\n\nExclusion Criteria:\n\n* Minors: Patients under 18 years of age.\n* Patients who do not provide informed consent.\n* Patients undergoing endoscopy on an emergency basis (defined as urgent diagnostic or therapeutic endoscopy performed on the gastrointestinal (GI) tract to address potentially life-threatening conditions or severe symptoms that require immediate medical attention).\n* An American Society of Anesthesiologists (ASA) physical status classification greater than 3.",{"count":102,"type":21},3000,"OBSERVATIONAL","The goal of this prospective observational study is to assess the accuracy and reliability of laser readings obtained through AccuMeasure, in comparison to other measurements performed by gastroenterologists. AccuMeasure is a novel technology, that has emerged as a promising tool for measuring polyps and lesions during colonoscopies. The system employs laser-based measurements, enabling precise determination of lesion size, depth, and extent. The main hypotheses this study aims to evaluate are:\n\n* AccuMeasure technology, with its precise laser measurements, will demonstrate superior accuracy and reliability in assessing lesion size of pathologies encountered during endoscopies, when compared to other endoscopic scoring methods.\n* AccuMeasure measurements will show strong construct validity by correlating significantly with endoscopic subscores, symptomatic remission (CD PRO2 \\\u003C8, partial mayo score), and fecal calprotectin values.",[106,107],"Polyp of Colon","Crohn Disease","2026-08-13",{"date":110,"type":32},"2026-08-18",{"date":112,"type":32},"2025-05-09",{"date":114,"type":21},"2027-11",{"name":38,"class":39},1,{"id":118,"slug":119,"hasResults":12,"nctId":120,"briefTitle":121,"officialTitle":121,"acronym":122,"eligibilityCriteria":123,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":124,"targetDuration":4,"studyType":22,"phases":126,"briefSummary":127,"conditions":128,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":130,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":135,"locationsCount":116},"100611610","reducing-neoplasia-recurrence-after-non-thermal-endoscopic-resection-of-large-colorectal-polyps-100611610","NCT07242820","Reducing Neoplasia Recurrence After Non-thermal Endoscopic Resection of Large Colorectal Polyps","COSA-RCT","Inclusion Criteria:\n\n* Adult patients\n* Undergoing EMR for large (≥20 mm) colorectal LSL\n* Providing written and informed consent for study participation\n\nExclusion Criteria:\n\n* Inflammatory bowel disease\n* Non-elective colonoscopy\n* Poor general health (American Society of Anesthesiologists classification \\>III)\n* Coagulopathy or thrombocytopenia (international normalized ration ≥1.5 or platelets \\\u003C50\\*10\\^9\u002FL)\n* Bulky lesions (granular mixed with ≥10mm module).",{"count":125,"type":21},752,[24],"The goal of this clinical trial is to clarify the role of adjuvant thermal ablation for non-thermal endoscopic mucosal resection (EMR) of large (≥20mm) flat colorectal polyps (so-called laterally spreading lesions \\[LSLs\\]).\n\nThe hypothesis is that adding adjuvant thermal ablation to non-thermal EMR (vs no ablation) will result in lower lesion recurrence rates at 6-month follow-up, and non-inferior adverse events (AE) rates 14 days post EMR.\n\nFor participants with planned EMR, endoscopists will perform non-thermal EMRs as per standard of care and:\n\n* adjuvant thermal ablation will either not be performed (control group), or will be applied to the base and outside margins of the resection site (experimental group);\n* then, all patients will be contacted 14-44 days after EMR, to verbally ascertain the occurrence of AEs;\n* then, all patients will undergo a first follow-up colonoscopy at 6 months after initial conoloscopy to assess lesion recurrence;\n* finally, all patients will undergo a second and final colonoscopy 18 months after EMR.",[129,106],"Colorectal Cancer",{"date":86,"type":32},{"date":132,"type":21},"2026-12",{"date":134,"type":21},"2032-05",{"name":38,"class":39},{"id":137,"slug":138,"hasResults":12,"nctId":139,"briefTitle":140,"officialTitle":141,"acronym":142,"eligibilityCriteria":143,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":144,"targetDuration":4,"studyType":22,"phases":146,"briefSummary":148,"conditions":149,"keywords":152,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":158,"startDateStruct":159,"completionDateStruct":161,"leadSponsor":163,"locationsCount":116},"100583588","phase-2-post-operative-radiotherapy-after-neodjuvant-chemo-immunotherapy-and-surgery-in-stage-iii-nsclc-100583588","NCT06878274","Post-operative Radiotherapy After Neodjuvant Chemo-immunotherapy and Surgery in Stage III NSCLC","Radiotherapy to Optimize Event-free Survival Following Chemo-Immunotherapy and Surgery in Upper Stage III NSCLC With Evidence of Pathological Residual Disease (RESCUE): Phase II Trial","RESCUE","Inclusion Criteria:\n\n1. Participants must be ≥ 18 years old\n2. Ability to provide written informed consent\n3. ECOG performance status 0-2\n4. Histologically confirmed NSCLC\n5. Absence of actionable driver mutation (EGFR\u002FALK\u002FROS)\n6. Complete preoperative imaging staging, including: FDG-PET and brain imaging to exclude distant metastases will be mandatory.\n7. Baseline clinical or post-operative pathological stage III including specifically stage T1-4N2-3\n8. Completion of 2-4 cycles of neoadjuvant chemo-IO, regardless of the specific immunotherapy and chemotherapy used.\n9. Status post-complete (R0) surgical resection with mediastinal lymph node dissection.\n10. Residual nodal disease on final pathology specimen (i.e. absence of pathological complete response).\n11. Postoperative lung function examination: FEV1 \\> 1 L (or greater than 35% expected value)\n\nExclusion Criteria:\n\n1. Pregnant individuals\n2. Previous chest radiotherapy\n3. \\>24 weeks after thoracic surgery\n4. History of other non-cutaneous neoplasms within the last 24 months\n5. Active grade ≥ 2 pneumonitis.\n6. Presence of interstitial lung disease\n7. Recurrence or metastasis occurred\n8. Medical conditions that hinders the safe administration of radiotherapy or follow-up.",{"count":145,"type":21},118,[147],"PHASE2","This study investigates whether postoperative radiotherapy (PORT) improves outcomes for patients with stage III non-small cell lung cancer (NSCLC) who have residual disease after neoadjuvant chemo-immunotherapy and surgery. The primary objective is to compare event-free survival (EFS) between patients receiving PORT targeting involved lymph node regions and those without PORT. Secondary and tertiary endpoints include overall survival, locoregional and distant control, toxicity, and quality of life. The phase II randomized trial will enroll 118 patients, stratifying by adjuvant immunotherapy use, with follow-up extending up to 5 years. Statistical analysis aims to detect a 15% improvement in 2-year EFS, with a total study duration of 7 years.",[150,151],"Non Small Cell Lung Cancer","Stage III Lung Cancer",[153,154,155,156,157],"Post operative radiotherapy","lung cancer","non small cell lung cancer","stage III lung cancer","neoadjuvant immunotherapy",{"date":86,"type":32},{"date":160,"type":32},"2026-01-29",{"date":162,"type":21},"2032-02",{"name":38,"class":39},{"id":165,"slug":166,"hasResults":12,"nctId":167,"briefTitle":168,"officialTitle":169,"acronym":170,"eligibilityCriteria":171,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":172,"targetDuration":4,"studyType":22,"phases":174,"briefSummary":175,"conditions":176,"keywords":180,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":185,"startDateStruct":186,"completionDateStruct":188,"leadSponsor":190,"locationsCount":191},"100573230","phase-iii-study-of-neoadjuvant-cemiplimab-and-dupilumab-in-early-stage-non-small-cell-lung-cancer-100573230","NCT06743581","Study of Neoadjuvant Cemiplimab and Dupilumab in Early-Stage Non-Small Cell Lung Cancer","Phase I\u002FII Study of Combined Treatment With Cemiplimab (Anti-PD-1) and Dupilumab (Anti-IL-4R) in Patients With Early-stage, Resectable NSCLC","Dupi-Cemi","Inclusion Criteria:\n\n* Histological confirmation of NSCLC is required before treatment (however, patients with a smoking history and radiographic findings suggestive of NSCLC may consent prior to biopsy to combine research and diagnostic procedures.\n* Age ≥ 18 years.\n* ECOG performance status 0-1\n* Determined to be a surgical candidate for tumor resection by a multidisciplinary team.\n* Women of childbearing potential and men must use approved contraception during the study and for 4 months post-treatment. Pregnancy or suspected pregnancy must be reported immediately.\n* Adequate organ and marrow function.\n* Pre-treatment biopsies are mandatory, and tumors must be T1b or larger (\\>1cm) and amenable to biopsy as determined by a multidisciplinary team.\n* Patients must consent to provide blood at designated study time points.\n* Patients must consent to core needle biopsies (at least 3 samples, as deemed safe by the performing surgeon\u002Fradiologist) prior to treatment initiation\n\nExclusion Criteria:\n\n* History of autoimmune disorders or use of immunomodulatory drugs (including dupilumab) within 2 months prior to treatment initiation.\n* Active autoimmune disease requiring systemic treatment in the past year, excluding replacement therapies like thyroxine or insulin.\n* Use of immunosuppressive drugs or systemic steroids within 7 days prior to treatment, except chronic steroids ≤10mg prednisone or equivalent.\n* No smoking history or confirmed tissue or ctDNA evidence of actionable driver alterations (e.g. EGFR mutation, ALK, or ROS1 rearrangements)\n* Prior chemotherapy or radiotherapy for another primary tumor, or prior locoregional therapy to the target lesion. Therapy for a different cancer is acceptable.\n* Metastatic disease where surgery would not have curative intent.\n* Uncontrolled illness, including active infections requiring antibiotics, symptomatic heart failure, unstable angina, or psychiatric\u002Fsocial conditions impeding study compliance.\n* Pregnancy or nursing, due to potential harm to the fetus or infant.\n* Progressive malignancy requiring active treatment, except for certain stable cancers treated with curative intent\n* HIV infection with detectable viral load or not on a stable HAART regimen\n* Active Hepatitis B or C (PCR-detectable)\n* History of allogeneic hematopoietic or solid organ transplantation.\n* Documented hypersensitivity to protein therapeutics.\n* Any condition, therapy, or abnormality that may interfere with trial results, patient participation, or their best interest as per the investigator's judgment.",{"count":173,"type":21},24,[24],"This phase 1b\u002F2a study evaluates the safety, feasibility, and efficacy of combining dupilumab (anti-IL-4Rα) and cemiplimab (anti-PD-1) in patients with early-stage, resectable NSCLC. Phase 1b focuses on safety and feasibility, using a 3+3 design to monitor dose-limiting toxicities (DLTs), while Phase 2a assesses the major pathological response (MPR) rate with a Simon's two-stage minimax design. Secondary endpoints include event-free survival, overall survival, and translational objectives such as deep immune monitoring from patient samples, with the trial expected to enroll 24 patients at CHUM over five years.",[177,178,179],"Non-Small Cell Lung Cancer","Immunotherapy","Neoadjuvant Therapy",[181,182,183,184],"NSCLC","Neoadjuvant immunotherapy","Cemiplimab","Dupilumab",{"date":29,"type":32},{"date":187,"type":32},"2025-08-19",{"date":189,"type":21},"2030-02",{"name":38,"class":39},2,{"id":193,"slug":194,"hasResults":12,"nctId":195,"briefTitle":196,"officialTitle":197,"acronym":198,"eligibilityCriteria":199,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":200,"targetDuration":4,"studyType":22,"phases":202,"briefSummary":204,"conditions":205,"keywords":208,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":212,"startDateStruct":213,"completionDateStruct":215,"leadSponsor":216,"locationsCount":116},"100573228","phase-1-surgery-after-verifying-existing-disease-in-locally-advanced-operable-lung-cancer-a-pilot-study-100573228","NCT06743555","Surgery After Verifying Existing Disease in Locally Advanced Operable Lung Cancer: A Pilot Study","Surgery After Verifying Existing Disease in Locally Advanced Operable Lung Cancer (SAVED LUNG Study): A Pilot Study","SAVED LUNG","Inclusion Criteria:\n\n* \\> 18 years of age\n* The participant has provided documented informed consent for the trial.\n* Histologically confirmed (by core biopsy) NSCLC and confirmed clinical stages II-III (excluding N2) NSCLC (AJCC 8th edition) amenable to receive neoadjuvant chemo-immunotherapy defined by: nivolumab 3mg\u002Fkg Q3W in combination with platinum doublet chemotherapy (cisplatin or carboplatin with paclitaxel or pemetrexed Q3W) for 3 cycles.\n* PD-L1 tumor proportion score \\>50%\n* Has no history of immunodeficiency, HBV, HCV, HIV.\n* For female participants:\n\n  1. Has no active pregnancy (Refer to \"Female participants\").\n  2. For a woman of child-bearing potential (WOCBP), use of a contraceptive method that is highly effective (with a failure rate of \\\u003C1% per year), with low user dependency, or be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long-term and persistent basis) during the intervention period and for at least 180 days after the last dose of study intervention and agrees not to donate eggs (ova, oocytes) to others or freeze\u002Fstore for her own use for the purpose of reproduction during this period.\n  3. A WOCBP must have a negative highly sensitive pregnancy test (\\[urine or serum\\] as required by local regulations) within either 24 hours (urine) or 72 hours (serum) before the first dose of study intervention.\n  4. If a urine test cannot be confirmed as negative (eg, an ambiguous result), a serum pregnancy test is required. In such cases, the participant must be excluded from participation if the serum pregnancy result is positive.\n* Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.\n* Has adequate hematological, renal and hepatic function per Investigator discretion required for platinum-doublet chemotherapy plus immunotherapy.\n* Has signed the written consent.\n\nExclusion Criteria:\n\n* Has one of the following tumor locations\u002Ftypes:\n\n  1. NSCLC involving the superior sulcus\n  2. Large cell neuro-endocrine cancer (LCNEC)\n  3. Sarcomatoid tumor\n* Has a history of (non-infectious) pneumonitis\u002Finterstitial lung disease that required steroids or has current pneumonitis\u002Finterstitial lung disease.\n* Has an active infection requiring systemic therapy.\n* Has had an allogenic tissue\u002Fsolid organ transplant.\n* Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the participant's participation for the full duration of the trial, or is not in the best interest of the participant to participate, in the opinion of the treating investigator.\n* Has known psychiatric or substance abuse disorders that would interfere with cooperating with the requirements of the trial.\n* Has a known additional malignancy that is progressing or requires active treatment within the past (5 years). Note: Participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, bladder carcinoma, or carcinoma in situ (eg, in situ cervical cancer or breast carcinoma) that have undergone potentially curative therapy are not excluded.",{"count":201,"type":21},14,[203],"PHASE1","The SAVED LUNG study is a pilot Phase I trial evaluating safety and feasibility of observation versus standard-of-care surgery in operable Stage II-III (excluding N3) NSCLC patients (PD-L1 ≥50%) who achieve complete clinical response following neoadjuvant platinum-doublet chemotherapy and immunotherapy. Participants are randomized to observation or surgery after rigorous restaging, with primary endpoints focusing on safety and feasibility. Secondary objectives include rates of cross-over to surgery, event-free survival, and overall survival, while exploratory endpoints examine ctDNA clearance and its association with clinical response.",[177,178,179,206,207],"Thoracic Surgery","Complete Response",[181,182,209,210,211],"Complete response","Surveillance","PD-L1",{"date":86,"type":32},{"date":214,"type":21},"2026-10-01",{"date":162,"type":21},{"name":38,"class":39},{"id":218,"slug":219,"hasResults":12,"nctId":220,"briefTitle":221,"officialTitle":221,"acronym":4,"eligibilityCriteria":222,"healthyVolunteers":12,"sex":223,"minAge":18,"maxAge":4,"enrollmentInfo":224,"targetDuration":4,"studyType":22,"phases":226,"briefSummary":227,"conditions":228,"keywords":230,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":232,"startDateStruct":233,"completionDateStruct":235,"leadSponsor":237,"locationsCount":116},"100533205","breast-cancer-plasma-adjuvant-intra-operative-treatment-breast-cancer-paint-100533205","NCT06222788","Breast Cancer Plasma Adjuvant Intra-operative Treatment (Breast Cancer PAINT)","Inclusion Criteria:\n\n1. Age ≥18 years at the time of signing study consent.\n2. ECOG ≤2.\n3. Patient with T1-4 breast cancer for groups A and B; patient with T1\u002FT2 breast cancer for group C (based on physical exam, not radiological measurements).\n4. Patient is scheduled to undergo a lumpectomy.\n\nExclusion Criteria:\n\n1. Prior treatment for the tumor of interest (including chemotherapy, immunotherapy, radiotherapy).\n2. Patient planning to or undergoing intraoperative radiotherapy.\n3. Diabetes (types I and II).\n4. Hypercortisolism.\n5. Collagen vascular disease.\n6. Patient requiring systemic corticosteroids at physiologic doses exceeding 10 mg\u002Fday of prednisone or its equivalent.\n7. Patient receiving daily chemotherapy for rheumatological conditions.\n8. Pregnancy (a urine pregnancy test must be obtained for non-sterile women of childbearing potential prior to surgery).","FEMALE",{"count":225,"type":21},30,[24],"The goal of this clinical trial is to test the safety of the use of non-thermal plasma (NTP, an ionized gas) on the tumor bed after the removal of the tumor in breast cancer patients. The main questions it aims to answer are:\n\n* To determine the safe and tolerable dose of NTP in patients with breast cancer;\n* To assess the safety and tolerability of NTP;\n* To assess the cosmetic effects of NTP treatment in patients with breast cancer. Participants will receive one treatment of the tumor bed after the removal of their breast tumor.",[229],"Breast Cancer",[231],"non-thermal plasma",{"date":86,"type":32},{"date":234,"type":32},"2025-04-07",{"date":236,"type":21},"2028-12",{"name":38,"class":39},{"id":239,"slug":240,"hasResults":12,"nctId":241,"briefTitle":242,"officialTitle":243,"acronym":244,"eligibilityCriteria":245,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":246,"targetDuration":4,"studyType":22,"phases":248,"briefSummary":249,"conditions":250,"keywords":254,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":258,"startDateStruct":259,"completionDateStruct":261,"leadSponsor":263,"locationsCount":116},"100382580","endovascular-acute-stroke-intervention---tandem-occlusion-trial-100382580","NCT04261478","Endovascular Acute Stroke Intervention - Tandem OCclusion Trial","A Multi-centre, Prospective, Randomized, Open-label, Blinded Endpoint (PROBE) Controlled Trial Comparing Cervical Internal Carotid Artery Stenting to no Stenting During Thrombectomy for Tandem Occlusion Stroke","EASI-TOC","Inclusion Criteria:\n\n* Acute ischemic anterior circulation stroke eligible for endovascular therapy according to local guidelines, with or without prior intravenous thrombolysis:\n\n  * Occlusion of the carotid terminus, M1 or M2 segments of the middle cerebral artery (MCA)\n  * A neurological deficit judged to be disabling by the patient and\u002For treating physician\n  * Any acute imaging judged by the treating physician to demonstrate salvageable brain tissue possibly amenable to EVT\n  * Groin puncture within 24-hours of onset or last known normal\n* Tandem ipsilateral high-grade (≥70%) cervical internal carotid artery (ICA) stenosis or occlusion of presumed atherosclerotic etiology on initial non-invasive vascular imaging\n* Informed consent from patient or surrogate or deferral of consent, according to local ethics policies\n\nExclusion Criteria:\n\n* Pre-existing neurological impairment (modified Rankin score ≥3)\n* Any underlying disease or condition making protocol adherence and\u002For 3-month follow-up unlikely\n* Any known contra-indication to EVT, angioplasty\u002Fstenting, or antiplatelet therapy\n* Tandem ipsilateral high-grade (≥70%) cervical internal carotid artery (ICA) stenosis or occlusion NOT confirmed on conventional angiography\n* Ipsilateral ICA stenosis or occlusion attributable to clinically or radiologically confirmed arterial dissection\n* Isolated cervical carotid occlusion without intracranial occlusion\n* Pregnancy",{"count":247,"type":21},458,[24],"Patients with tandem occlusion or tandem lesion (TL), that is, stroke with an acute intracranial anterior circulation occlusion and an ipsilateral cervical ICA (c-ICA) high-grade stenosis or occlusion, constitute about 15-20% of patients undergoing endovascular thrombectomy (EVT).\n\nHowever, the optimal treatment of acute stroke patients with TL remains uncertain, as relatively few patients with TL were included in the major randomized controlled trials of EVT and management of the c-ICA was generally not specified by protocol nor analyzed post-hoc.\n\nRecent large multi-centre retrospective cases series suggest that acutely stented patients may have more favorable outcomes than patients treated with angioplasty alone or those with no acute ICA intervention, but high quality randomized trial data are lacking.\n\nEASI-TOC, a phase 3, academic multi-centre, controlled trial (PROBE design) with embedded pilot phase, will seek to determine if in patients undergoing acute intracranial thrombectomy for anterior circulation stroke with concurrent ipsilateral symptomatic high-grade (≥70%) atherosclerotic stenosis or occlusion of the extracranial ICA, endovascular ICA revascularization with stenting is superior to intracranial thrombectomy alone with regards to functional outcome at 90 days. Patients will be randomized to Acute stenting or No acute stenting (1:1 allocation).",[251,252,253],"Stroke, Acute","Carotid Stenosis","Carotid Artery Diseases",[255,256,257],"Thrombectomy","Tandem occlusion","Carotid stenting",{"date":86,"type":32},{"date":260,"type":32},"2020-08-31",{"date":262,"type":21},"2027-10",{"name":38,"class":39},{"id":265,"slug":266,"hasResults":12,"nctId":267,"briefTitle":268,"officialTitle":269,"acronym":270,"eligibilityCriteria":271,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":272,"targetDuration":274,"studyType":103,"phases":4,"briefSummary":275,"conditions":276,"keywords":279,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":284,"startDateStruct":285,"completionDateStruct":287,"leadSponsor":289,"locationsCount":116},"100371353","attribution-of-toxicities-due-to-radiotherapy-and-immuno-biological-therapies-100371353","NCT04115267","Attribution of Toxicities Due to Radiotherapy and Immuno-Biological Therapies","Attribution of Toxicities Due to Radiotherapy and Immuno-Biological Therapies - Registry","AtTRIBut","Inclusion Criteria:\n\n* Consent to be part of the AtTRIBut registry\n* Prior histological diagnosis of primary cancer.\n* If the patient has metastatic disease, there must be radiological or pathological evidence of metastasis\n* Age\\> 18 years\n* Receiving a molecular therapy\n* Indicated to receive radiotherapy\n* Radiation therapy can be administered using 3D conventional, IMRT or SBRT techniques.\n\nExclusion Criteria:\n\n• Refusal or inability to receive radiotherapy",{"count":273,"type":21},3600,"1 Year","Every year, new molecular agents enter the market with more and more patients receiving these treatments, especially in the metastatic setting. These molecular agents could correspond to immunotherapy and modulators of signaling pathways. More than 50% of cancer patients will receive radiation therapy during the course of their illness, including radiotherapy aimed a palliating symptoms secondary to metastatic diseases. Therefore, there will be an increasing number of patients who will be receiving radiotherapy while they are still receiving molecular agents. A better understanding of the interaction of these two treatment modalities is needed.",[277,278],"Cancer","Radiotherapy Side Effect",[280,281,282,283,277],"Combined effect","Registry","Side effects","Patient reported outcome",{"date":86,"type":32},{"date":286,"type":32},"2019-09-13",{"date":288,"type":21},"2030-09-30",{"name":38,"class":39},{"id":291,"slug":292,"hasResults":12,"nctId":293,"briefTitle":294,"officialTitle":295,"acronym":296,"eligibilityCriteria":297,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":298,"targetDuration":300,"studyType":103,"phases":4,"briefSummary":301,"conditions":302,"keywords":4,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":304,"lastUpdatePostDateStruct":305,"startDateStruct":307,"completionDateStruct":309,"leadSponsor":311,"locationsCount":116},"100579324","videoimage-library-of-endoscopy-procedures-for-the-development-of-ai-empowered-endoscopy-quality-reporting-and-educational-modules-100579324","NCT06822816","Video\u002FImage Library of Endoscopy Procedures for the Development of AI-empowered Endoscopy Quality Reporting and Educational Modules","Creation of a Video\u002FImage Library of Annotated Full-length Endoscopy Procedures for the Development of Artificial Intelligence-empowered Endoscopy Quality Reporting and Educational Modules","Videotheque","Inclusion Criteria:\n\n* ≥ 18 y.o.\n* indication of undergoing a screening, surveillance, diagnostic, or therapeutic upper (EGD) or lower (colonoscopy) endoscopy\n\nExclusion Criteria:\n\n* Coagulopathy defined as an elevated INR ≥ 2.5\n* Platelet count ≤ 50,000\u002Fmm3\n* Emergency endoscopy\n* Poor general health defined as the American Society of Anesthesiologists physical status class \\>3",{"count":299,"type":21},10000,"5 Years","The goal of this observational study is to establish a video\u002Fimage library dataset of complete endoscopy or partial colonoscopy procedures for patients with rectal cancer or inflammatory bowel disease (IBD). With this video\u002Fimage library, the aims are:\n\n* to develop and validate novel AI-empowered solutions to automatically detect and report endoscopy quality metrics\n* to develop automated endoscopy reporting solutions, auditing, and educational tools for residents and fellows to enhance their endoscopy skills.\n\nThe hypothesis is that a heterogeneous video\u002Fimage library will provide:\n\n* comprehensive and robust source material to develop AI models\n* real-time quality feedback at the end of an endoscopy procedure.",[106,303],"Artificial Intelligence (AI)","2026-08-09",{"date":306,"type":32},"2026-08-11",{"date":308,"type":32},"2022-06-10",{"date":310,"type":21},"2028-12-31",{"name":38,"class":39},{"id":313,"slug":314,"hasResults":12,"nctId":315,"briefTitle":316,"officialTitle":317,"acronym":318,"eligibilityCriteria":319,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":320,"targetDuration":4,"studyType":22,"phases":322,"briefSummary":323,"conditions":324,"keywords":4,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":304,"lastUpdatePostDateStruct":325,"startDateStruct":326,"completionDateStruct":328,"leadSponsor":330,"locationsCount":116},"100578113","complete-closure-after-endoscopic-mucosal-resection-of-large-non-pedunculated-colorectal-polyps-100578113","NCT06807073","Complete Closure After Endoscopic Mucosal Resection of Large Non-Pedunculated Colorectal Polyps","Complete Closure After Endoscopic Mucosal Resection of Large Non-Pedunculated Colorectal Polyps: A Randomized Controlled Trial","Closure-RCT","Inclusion Criteria:\n\n* adult ≥18 years old\n* patients undergoing EMR for a large (≥20mm) colorectal LSL\n* patients providing written and informed consent for study participation.\n\nExclusion Criteria:\n\n* inflammatory bowel disease;\n* non-elective colonoscopy;\n* poor general health (American Society of Anesthesiologists classification \\>III);\n* coagulopathy or thrombocytopenia (international normalized ratio ≥1.5 or platelets \\\u003C50 x 109\u002FL);\n* pedunculated polyps (Paris class Ip, Isp);\n* overt signs of deep submucosal invasive cancer (JNET 3);\n* appendiceal orifice or terminal ileum invasion;\n* pregnancy.",{"count":321,"type":21},686,[24],"The goal of this clinical trial is to compare adverse even rates after EMR for large (≥20mm) flat colorectal polyps (so-called laterally spreading lesions, LSLs) when performing complete or no defect closure. It will also evaluate lesion recurrence after EMR for large colorectal LSLs.\n\nThe hypothesis is that performing complete defect closure following EMR of large colorectal LSLs will result in lower rates of adverse events compared to cases where no defect closure is performed.\n\nFor participants with planned EMR, endoscopists will perform EMRs as per standard of care and:\n\n* prophylactic defect closure will either not be performed (control group), or will be performed (experimental group);\n* then, patients will be called between 14 and 44 days after EMR to assess for possible adverse events, and electronic medical files will be verified for emergency room visits and healthcare received for an adverse event;\n* finally, patients will undergo follow-up colonoscopy 6 months and 18 months after randomization.",[129,106],{"date":306,"type":32},{"date":327,"type":32},"2025-02-27",{"date":329,"type":21},"2027-07",{"name":38,"class":39},{"id":332,"slug":333,"hasResults":12,"nctId":334,"briefTitle":335,"officialTitle":335,"acronym":336,"eligibilityCriteria":337,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":338,"targetDuration":340,"studyType":103,"phases":4,"briefSummary":341,"conditions":342,"keywords":4,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":304,"lastUpdatePostDateStruct":345,"startDateStruct":346,"completionDateStruct":348,"leadSponsor":350,"locationsCount":116},"100371494","advanced-endo-therapeutic-procedure--registry-based-observational-study-100371494","NCT04117100","Advanced Endo-therapeutic Procedure : Registry-based Observational Study","AE Registry","Inclusion Criteria:\n\n* Age \\>18 years\n* Presenting for an elective advanced therapeutic endoscopy (ESD, EMR, advanced polypectomy, POEM or Zenker treatment)\n* Signed informed consent form\n\nExclusion Criteria:\n\n* Patients that are not capable understanding the trial and patients without consent.\n* Patients with coagulopathy\n* Patient with poor general health defined as an American Society of Anesthesiologists class greater than three\n* Pregnancy",{"count":339,"type":21},500,"20 Years","Advanced therapeutic endoscopy procedures are of increasing importance to provide minimal invasive treatment for GI diseases. The Centre Hospitalier de l'Université de Montréal as tertiary university center is dedicated to increase the availability of therapeutic endoscopy procedures for our population in Montreal and Quebec. Advanced endotherapeutic endoscopy can replace surgery for treatment of benign and malign GI diseases and the aim of this registry-based study is to improve quality related to advanced endotherapeutic endoscopy, as it will provide quantitative means to assess advanced endotherapeutic practice and may identify practices of low quality (possible intervention) or high quality (desired).",[343,106,344],"Zenker Diverticulum","Colo-rectal Cancer",{"date":306,"type":32},{"date":347,"type":32},"2018-06-13",{"date":349,"type":21},"2026-12-31",{"name":38,"class":39},{"id":352,"slug":353,"hasResults":12,"nctId":354,"briefTitle":355,"officialTitle":356,"acronym":357,"eligibilityCriteria":358,"healthyVolunteers":12,"sex":17,"minAge":359,"maxAge":360,"enrollmentInfo":361,"targetDuration":4,"studyType":103,"phases":4,"briefSummary":363,"conditions":364,"keywords":368,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":380,"lastUpdatePostDateStruct":381,"startDateStruct":383,"completionDateStruct":385,"leadSponsor":387,"locationsCount":4},"100649768","ai-assisted-optical-diagnosis-cadx-for-diminutive-colorectal-polyps-100649768","NCT07738484","AI-Assisted Optical Diagnosis (CADx) for Diminutive Colorectal Polyps","Prospective Multicenter Validation of an Artificial Intelligence-Assisted Optical Diagnosis Strategy (CADx) for the Real-Time Characterization of Diminutive Colorectal Polyps: A STARD-Compliant Diagnostic Accuracy Study","CADxGIG","Inclusion Criteria:\n\n* Signed informed consent, obtained before the colonoscopy and before sedation\n* Age 45-80 years\n* Indication for elective colonoscopy (screening, surveillance, or diagnostic)\n* At least one diminutive polyp (≤5 mm) detected during the procedure (required for inclusion in the analytic cohort; consented patients without an eligible polyp are documented as screen failures)\n\nExclusion Criteria:\n\n* Known inflammatory bowel disease\n* Active colitis\n* Coagulopathy or thrombocytopenia (INR ≥1.5 or platelets \\\u003C50×10⁹\u002FL)\n* Familial polyposis syndrome\n* American Society of Anesthesiologists classification \\>III\n* Emergency colonoscopy\n* Inadequate bowel preparation (Boston Bowel Preparation Scale \\\u003C6)","45 Years","80 Years",{"count":362,"type":21},840,"This study evaluates whether an artificial intelligence system (GI Genius, Medtronic), already approved by Health Canada, can help doctors accurately identify, in real time during colonoscopy, which small colorectal polyps (5 mm or less) need to be monitored (adenomas) versus those that do not (for example, hyperplastic polyps). For each small polyp found, the endoscopist will first record a diagnosis without the help of the artificial intelligence system, then activate the system and record a second diagnosis after seeing its assessment. Both diagnoses will be compared to the final result from standard pathology testing, which remains the reference standard. This is an observational diagnostic accuracy study: it does not change any clinical care. All polyps continue to be removed and sent for pathology analysis as usual, whether or not the artificial intelligence system agrees with the doctor. The study will take place during colonoscopies already scheduled for standard clinical reasons (screening, surveillance, or diagnostic work-up), with no additional visits, blood draws, imaging, or sedation. Approximately 840 participants will be enrolled across three Canadian centres (Santé Québec - CHUM, McGill University Health Centre, and St. Paul's Hospital, Vancouver). The goal is to determine whether this AI-assisted approach helps doctors reach the internationally recognized performance thresholds (at least 80% sensitivity and 80% specificity) needed to support clinical adoption of real-time optical diagnosis, which could eventually reduce unnecessary pathology testing.",[365,366,367],"Colorectal Polyps","Colorectal Adenoma","Diminutive Colorectal Polyp",[369,370,371,372,373,366,374,375,376,377,378,379],"CADx","Computer-Aided Diagnosis","Optical Diagnosis","Colonoscopy","Diminutive Colorectal Polyps","GI Genius","Artificial Intelligence","Diagnostic Accuracy","Real-time Characterization","STARD","Histopathology","2026-07-29",{"date":382,"type":32},"2026-07-31",{"date":384,"type":21},"2026-08",{"date":386,"type":21},"2029-08",{"name":38,"class":39},{"id":389,"slug":390,"hasResults":12,"nctId":391,"briefTitle":392,"officialTitle":393,"acronym":394,"eligibilityCriteria":395,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":396,"targetDuration":4,"studyType":22,"phases":398,"briefSummary":399,"conditions":400,"keywords":403,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":406,"lastUpdatePostDateStruct":407,"startDateStruct":409,"completionDateStruct":411,"leadSponsor":413,"locationsCount":116},"100438472","phase-2-stereotactic-ablative-radiotherapy-for-oligo-progressive-disease-refractory-to-systemic-therapy-in-metastatic-cancer-100438472","NCT04989725","Stereotactic Ablative Radiotherapy for Oligo-Progressive Disease REfractory to Systemic Therapy in Metastatic Cancer","Stereotactic Ablative Radiotherapy for Oligo-Progressive Disease REfractory to Systemic Therapy in Metastatic Cancer: A Phase II Randomized Trial","SUPPRESS","Inclusion Criteria:\n\n* Age ≥18 years\n* Metastatic cancer (any histology), with pathological or radiological proof of metastasis\n* Ability to provide written informed consent\n* Eastern Cooperative Oncology Group (ECOG) performance status 0-2\n* Progressive disease while on systemic treatment (any line), defined as per RECIST criteria 1.1 on CT metrics as a greater than 20% increase in the sum measurement of lesions, non-target unequivocal progressive disease or a new lesion on CT.\n* Oligoprogression to 1-5 extracranial lesions ≤ 5cm and involving ≤ 3 organs. Progression at the primary tumor site should be counted within the total of 5 lesions. For patients with lymph node metastases, each node is counted as one site of metastasis.\n* All sites of disease can, in the opinion of the investigator, be safely treated and targetable with SABR (taking into account prior local therapy, organ function and underlying medical condition such as inflammatory bowel disease, pulmonary fibrosis, etc.)\n* Patients with prior metastases that have been treated with ablative therapies (e.g. radiotherapy, surgery or radiofrequency ablation) before their current line of systemic therapy, are eligible.\n\nExclusion Criteria:\n\n* Pregnancy or breastfeeding\n* Any medical condition that could, in the opinion of the investigator, preclude radiotherapy or prevent follow-up after radiotherapy.\n* Presence of spinal cord compression\n* Metastatic disease that invades the GI tract (including esophagus, stomach, small or large bowel",{"count":397,"type":21},46,[147],"A registry-based randomized phase II trial. A total of 46 patients with metastatic cancer on systemic therapy with oligoprogression to 1-5 extracranial lesions will be randomized using a 1:1 ratio to standard of care (begin next-line systemic therapy, best supportive care, continue current systemic line, based on treating physician decision) vs. receive stereotactic ablative radiotherapy to all oligoprogressive lesions while continuing their current systemic therapy.",[401,402],"Metastatic Cancer","Oligoprogressive",[404,405],"metastatic cancer","oligoprogression","2026-07-21",{"date":408,"type":32},"2026-07-22",{"date":410,"type":32},"2021-10-01",{"date":412,"type":21},"2029-03-01",{"name":38,"class":39},{"id":415,"slug":416,"hasResults":12,"nctId":417,"briefTitle":418,"officialTitle":419,"acronym":420,"eligibilityCriteria":421,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":422,"targetDuration":4,"studyType":22,"phases":424,"briefSummary":425,"conditions":426,"keywords":429,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":436,"lastUpdatePostDateStruct":437,"startDateStruct":439,"completionDateStruct":441,"leadSponsor":443,"locationsCount":444},"100646057","restrictive-fluid-management-in-liver-transplantation-refil-100646057","NCT07695363","Restrictive Fluid Management In Liver Transplantation (REFIL)","Effects of an Intraoperative Low-splanchnic Blood Volume Restrictive Fluid Management Strategy Compared to a Cardiac Output Optimized Liberal Fluid Management Strategy on Postoperative Outcomes in Liver Transplantation: A Multicenter Randomized Controlled Trial (REFIL-2)","REFIL-2","Inclusion Criteria:\n\n1. Adult ≥ 18 years old\n2. Undergoing liver transplantation (LT)\n3. End-stage liver disease (ESLD) (with or without hepatocellular carcinoma) as the indication for transplantation.\n\nExclusion Criteria:\n\n1. Undergoing LT for an indication other than ESLD (e.g., acute liver failure, primary liver cancer without ESLD, retransplantation, amyloid neuropathy, polycystic liver disease, or any other indication not associated with ESLD)\n2. Undergoing combined solid organ transplantations\n3. Any of the following conditions:\n\n   * severe chronic renal failure (GFR \\\u003C 15 ml\u002Fminute\u002F1.73 m2 \\[CKD-EPI equation\\] or already on renal replacement therapy (RRT))\n   * severe anemia (hemoglobin level \\\u003C 80 g\u002FL)\n   * hemodynamic instability (norepinephrine equivalent \\> 10 ug\u002Fmin)\n4. Physician refusal to enroll the patient.",{"count":423,"type":21},866,[24],"The goal of the REFIL-2 study is to evaluate the effectiveness of a low splanchnic blood volume restrictive fluid management strategy (a strategy that involves limiting fluid administration and prioritizing the use of medications that raise blood pressure during surgery, combined with phlebotomy) in improving patients' recovery after surgery. The study compares the low splanchnic blood volume restrictive fluid management strategy to an optimized cardiac-output liberal fluid management strategy (which involves administering more fluids to raise blood pressure with less reliance on medications). Outcomes important to patients will be measured.\n\nThis study (REFIL-2) had a vanguard phase (internal pilot) that included 138 patients (NCT05647733). The patients included in the vanguard pilot phase were not compared between groups but only analyzed descriptively using aggregated data. Only feasibility metrics were compared (see NCT05647733). These 138 patients were thus rolled into the REFIL-2 trial and included in the final sample size reported herein.",[427,428],"Liver Transplantation (LT)","End-stage Liver Disease (ESLD)",[430,431,432,433,434,435],"Liver Transplantation","Phlebotomy","Hemodynamic Management","Fluid Management","Transfusions","Liver Diseases","2026-07-08",{"date":438,"type":32},"2026-07-10",{"date":440,"type":32},"2026-02-15",{"date":442,"type":21},"2031-11",{"name":38,"class":39},4,{"id":446,"slug":447,"hasResults":12,"nctId":448,"briefTitle":449,"officialTitle":450,"acronym":4,"eligibilityCriteria":451,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":452,"targetDuration":4,"studyType":22,"phases":453,"briefSummary":454,"conditions":455,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":457,"lastUpdatePostDateStruct":458,"startDateStruct":459,"completionDateStruct":461,"leadSponsor":462,"locationsCount":116},"100563618","manual-debridement-vs-phototherapeutic-keratectomy-in-the-treatment-of-corneal-basement-membrane-dystrophy-100563618","NCT06618508","Manual Debridement vs Phototherapeutic Keratectomy in the Treatment of Corneal Basement Membrane Dystrophy","Comparison of Efficacy and Safety Between Manual Debridement and Phototherapeutic Keratectomy (PTK) in the Treatment of Corneal Basement Membrane Dystrophy","Inclusion Criteria:\n\n* Patient over 18 years of age;\n* Ability to give free and informed consent\n* At least 1-year follow-up possible\n* Patients with bilateral basal membrane corneal dystrophy who are symptomatic (recurrent corneal erosions, visual disturbances) and are candidates for bilateral surgery.\n\nExclusion Criteria:\n\n* Patient under 18 years of age;\n* History of ocular infection with herpes simplex virus.",{"count":7,"type":21},[24],"Of the few comparisons made in the existing literature, the results of PTK are comparable to those documented for manual debridement (MD). However, the shorter length of follow-up in patients with MD may have underestimated the associated complications. Our study, therefore, aims to offer a comparison between these two techniques to clarify the choice of effective treatment with a good safety profile.",[456],"Epithelial Basement Membrane Dystrophy","2026-07-06",{"date":436,"type":32},{"date":460,"type":21},"2026-10",{"date":262,"type":21},{"name":38,"class":39},{"id":464,"slug":465,"hasResults":12,"nctId":466,"briefTitle":467,"officialTitle":468,"acronym":469,"eligibilityCriteria":470,"healthyVolunteers":471,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":472,"targetDuration":4,"studyType":22,"phases":474,"briefSummary":475,"conditions":476,"keywords":480,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":489,"lastUpdatePostDateStruct":490,"startDateStruct":492,"completionDateStruct":494,"leadSponsor":496,"locationsCount":497},"100520020","effects-of-probiotics-in-amyotrophic-lateral-sclerosis-frontotemporal-dementia-spectrum-disorder-als-ftdsd-patients-100520020","NCT06051123","Effects of Probiotics in Amyotrophic Lateral Sclerosis-Frontotemporal Dementia Spectrum Disorder (ALS-FTDSD) Patients","Effects of Probiotics on Lipidomic Profile and Disease Evolution in ALS-FTDSD Patients: A Randomized Multicenter, Double-blind, Phase II, Placebo-controlled, Parallel Trial.","PROBIOTIC","Inclusion criteria:\n\nParticipants must meet all of the following inclusion criteria to be eligible for enrolment into the study:ALS-FTDSD participants\n\n1. Aged 18 years old or greater.\n2. Diagnosis of ALS by El Escorial Criteria revised (possible, probable, probable with lab support and definite).\n3. Onset of weakness or speech impairment no more than 24 months before randomization.\n4. ALSFRS-R equal or superior to 24\u002F48 at screening, with no more than one subscore under 2\u002F4.\n5. SVC greater than or equal to 60% predicted for sex, age and height at screening.\n6. Note on FTD Symptoms: The presence of FTD symptoms is not a requirement for inclusion in this study. Participants with a diagnosis of ALS, whether or not accompanied by FTD symptoms, are eligible for inclusion. No prior or screening diagnosis of FTDSD is required.\n7. Subject has an informant\u002Fcaregiver who has frequent and sufficient contact to provide accurate information about the patient's cognitive abilities and behaviors to complete the ALS-CBS.\n8. Participants apt to comprehend and sign the ICF.\n9. Participants of child-bearing potential must have a negative serum pregnancy test at screening and agree to use a medically approved method of birth control for the duration of the study. All hormonal birth control must have been in use for a minimum of three months. Acceptable methods of birth control include:\n\n   * Abstinence or agrees to use contraception if planning to become sexually active.\n   * Hormonal contraceptives including oral contraceptives, hormone birth control patch, vaginal contraceptive ring, injectable contraceptives, or hormone implant\n   * Double-barrier method\n   * Intrauterine devices\n   * Non-heterosexual lifestyle or agrees to use contraception if planning on changing to heterosexual partner(s)\n   * Vasectomy of partner at least 6 months prior to screening\n10. Willing to maintain eating habits throughout the study.\n11. Willing to refrain from consuming probiotic supplements and food containing added probiotics and\u002For prebiotics (e.g., yogurts with live, active cultures or supplements) from the moment of screening until the end of the study.\n\nHealthy controls:\n\n1. Aged 18 years old or greater.\n2. Able to comprehend and willing to sign ICF.\n3. Participants of child-bearing potential must have a negative serum pregnancy test at screening and agree to use a medically approved method of birth control for the duration of the study. All hormonal birth control must have been in use for a minimum of three months. Acceptable methods of birth control include:\n\n   * Abstinence or agrees to use contraception if planning to become sexually active.\n   * Hormonal contraceptives including oral contraceptives, hormone birth control patch, vaginal contraceptive ring, injectable contraceptives, or hormone implant\n   * Double-barrier method\n   * Intrauterine devices\n   * Non-heterosexual lifestyle or agrees to use contraception if planning on changing to heterosexual partner(s)\n   * Vasectomy of partner at least 6 months prior to screening\n4. Willing to maintain eating habits throughout the study.\n5. Willing to refrain from consuming probiotic supplements and food containing added probiotics and\u002For prebiotics (e.g., yogurts with live, active cultures or supplements) from the moment of screening until the end of the study.\n\nInformant\u002Fcaregiver\n\n1. Aged 18 years old or greater.\n2. Has frequent and sufficient contact to provide accurate information about the patient's cognitive abilities and behaviors to complete the ALS-CBS.\n3. Able to comprehend and willing to sign ICF\n\nExclusion criteria:\n\nSubjects with any of the following characteristics\u002Fconditions will not be included in the study:\n\nALS-FTDSD participants\n\n1. Use of respiratory support (non-invasive ventilation or mechanical respiratory support) at screening.\n2. Significant medical condition or behavioral issues that could interfere with participation in the clinical trial in the principal investigator's opinion.\n3. Use of a feeding tube at randomization.\n4. Use of lipid-lowering drugs for less than 3 months before randomization.\n5. Introduction of lipid-lowering drug unless it is due to the event of acute coronary syndrome or stroke as per Canadian guidelines.\n6. Use of edaravone with stable dosage for less than 2 months before randomization.\n7. Use of riluzole with stable dosage for less than 1 month before randomization.\n8. Introduction of edaravone or riluzole during the clinical trial.\n9. Immunodeficiency (immune-compromised and immune-suppressed participants, e.g., AIDS, lymphoma, participants undergoing long-term corticosteroid treatment, chemotherapy and allograft participants).\n10. Pregnancy (as per serum HCG pregnancy test at screening), planning to be pregnant or currently breastfeeding.\n11. Use of probiotics other than the study medication in the month prior to randomization. Note: participants could be eligible to participate after a 4-week washout period.\n12. Use of any antibiotic drug in the month prior to randomization. Note: participants could be eligible to participate after a 4-week washout period.\n13. Milk and soy allergy, or severe lactose intolerance.\n14. Currently enrolled in another clinical trial.\n\nHealthy controls:\n\n1. Use of lipid-lowering drugs for less than 3 months before randomization.\n2. Introduction of lipid-lowering drug unless it is due to the event of acute coronary syndrome or stroke as per Canadian guidelines.\n3. Pregnancy (as per serum HCG pregnancy test at screening), planning to be pregnant or currently breastfeeding. Note: participants will not take the IP or placebo, but pregnancy is a major factor that could affect lipidomic profiling.\n4. Use of probiotics in the month prior to day 0 of the study (visit 2). Note: participants could be eligible to participate after a 4-week washout period. Although participants will not consume any study product, we aim to maintain environmental factors comparable to the ALS-FTDSD group.\n5. Use of any antibiotic drug in the month prior to day 0 of the study (visit 2). Note: participants could be eligible to participate after a 4-week washout period. Although participants will not consume any study product, we aim to maintain environmental factors comparable to the ALS-FTDSD group.\n6. Milk and soy allergy, or severe lactose intolerance. Note: Although participants will not consume any study product, we aim to maintain environmental factors comparable to the ALS-FTDSD group. We aim to exclude allergies, so participants are maintained on standard diet.\n7. Currently enrolled in another clinical trial.",true,{"count":473,"type":21},150,[24],"The aim of this study is to assess the impact of a probiotic formulation on participants with ALS-FTDSD. It is hypothesized that participants given the probiotics will have different lipid profiles compared to participants receiving the placebo at different time points.",[477,478,479],"ALSFTD","ALS (Amyotrophic Lateral Sclerosis)","Frontal Temporal Dementia (FTD)",[481,482,483,484,485,486,487,488],"ALS","FTD","motor function","probiotics","lipidomics","metabolites","neurofilament","microbiome","2026-06-26",{"date":491,"type":32},"2026-06-30",{"date":493,"type":32},"2024-01-01",{"date":495,"type":21},"2027-02",{"name":38,"class":39},3,{"id":499,"slug":500,"hasResults":12,"nctId":501,"briefTitle":502,"officialTitle":502,"acronym":4,"eligibilityCriteria":503,"healthyVolunteers":12,"sex":17,"minAge":504,"maxAge":4,"enrollmentInfo":505,"targetDuration":4,"studyType":22,"phases":507,"briefSummary":508,"conditions":509,"keywords":511,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":515,"lastUpdatePostDateStruct":516,"startDateStruct":518,"completionDateStruct":520,"leadSponsor":522,"locationsCount":4},"100643102","scar-management-through-serial-casting-100643102","NCT07645664","Scar Management Through Serial Casting","Inclusion Criteria:\n\n* adult burn survivors who have two scars that meet the diagnostic criteria of a HSc (erythema index greater than 300 and thickness greater than 2.034 mm) and with no more than 0.5 mm thickness difference between each other;\n* are proficient in English and\u002For French;\n* provide informed consent.\n\nExclusion Criteria:\n\n* patients who sustained electrical or cold injury;\n* formed keloid scars or have only mature scars (erythema index less than 300);\n* have a a dermatological condition that could interfere with measurement reliability (eczema, psoriasis);\n* have a cognitive\u002Fpsychiatric condition that could impaired understanding of the consent process or adherence to protocol procedures.","16 Years",{"count":506,"type":21},38,[24],"Scar management remains one of the major clinical challenges for burn survivors with hypertrophic scars. Beyond their visible appearance, hypertrophic scars can significantly impair physical function, reduce life satisfaction, and affect overall quality of life. According to the results of a recently completed study, the application of serial casts appears promising for the treatment of hypertrophic scars in adults who have survived a burn injury. However, this therapeutic approach has not yet been evaluated objectively in terms of scar characteristics within the context of a study with sufficient statistical power. The present project is the first study with sufficient statistical power to objectively evaluate the beneficial effects of serial casting on the characteristics of hypertrophic scars in adult burn survivors. The objective of this study is to characterize changes in thickness, elasticity, vascularization, transepidermal water loss (TEWL), itching, and pain in hypertrophic burn scars in adults after one week of treatment with serial dressings, compared to an intra-individual control scar. Our hypothesis is that relative to baseline measures the scar thickness (primary outcome), erythema index, TEWL, itch, and pain will decrease at treatment sites compared to control sites. Conversely, elasticity will increase at the treatment sites compared to control sites. This will be a prospective, longitudinal, evaluator-blinded, randomized intra-individual controlled trial.",[510],"Burn Scar",[512,513,514],"Burns","Burn Rehabilitation","Serial Casting","2026-06-09",{"date":517,"type":32},"2026-06-12",{"date":519,"type":21},"2026-06-01",{"date":521,"type":21},"2028-11",{"name":38,"class":39},{"id":524,"slug":525,"hasResults":12,"nctId":526,"briefTitle":527,"officialTitle":528,"acronym":4,"eligibilityCriteria":529,"healthyVolunteers":471,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":530,"targetDuration":4,"studyType":22,"phases":531,"briefSummary":532,"conditions":533,"keywords":4,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":519,"lastUpdatePostDateStruct":535,"startDateStruct":537,"completionDateStruct":539,"leadSponsor":541,"locationsCount":116},"100633307","joint-effort-20--evaluation-among-general-population-100633307","NCT07524985","Joint Effort 2.0 : Evaluation Among General Population","\" Joint Effort 2.0 \" Une Application Mobile de prévention et de réduction Des méfaits: évaluation auprès de Consommateurs de Cannabis","Inclusion Criteria:\n\n* Aged 18 years old or older\n* Be an active non-medical cannabis user (ie. self reported past month usage)\n* Understand, read and write French\n* Own a smartphone (iPhone)\n\nExclusion Criteria:\n\n* None",{"count":20,"type":21},[24],"This study aims to evaluate a mobile app designed to promote the safe use of cannabis among adult users in Quebec.",[534],"Cannabis Use",{"date":536,"type":32},"2026-06-03",{"date":538,"type":32},"2026-04-30",{"date":540,"type":21},"2027-04",{"name":38,"class":39},{"id":543,"slug":544,"hasResults":12,"nctId":545,"briefTitle":546,"officialTitle":547,"acronym":548,"eligibilityCriteria":549,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":360,"enrollmentInfo":550,"targetDuration":4,"studyType":22,"phases":552,"briefSummary":553,"conditions":554,"keywords":4,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":556,"lastUpdatePostDateStruct":557,"startDateStruct":559,"completionDateStruct":561,"leadSponsor":563,"locationsCount":116},"100288987","corneal-collagen-crosslinking-to-increase-the-resistance-of-the-support-graft-of-the-kpro-type-i-against-corneal-melting-100288987","NCT03041883","Corneal Collagen Crosslinking to Increase the Resistance of the Support Graft of the KPro Type I Against Corneal Melting","Corneal Collagen Crosslinking to Increase the Resistance of the Graft Used as a Support for the Boston Keratoprosthesis Type I Against Corneal Melting","CXL-KPro","Inclusion Criteria:\n\n* Candidate for KPro type I\n* Capacity to give written consent\n* Ability to be followed for the duration of the study\n\nExclusion Criteria:\n\n* Participation in another interventional study\n* Failure to wear a therapeutic contact lens due to abnormalities of the eyelids.\n* Inability to give written consent\n\nContraindications to the KPro type I:\n\n* Severe dryness with keratinization of the ocular surface\n* Intraocular tumor\n* Terminal glaucoma\n* Inoperable retinal detachment\n* Phthisis bulbi",{"count":551,"type":21},40,[24],"The purpose of this study is to demonstrate the safety and efficacy of the corneal collagen crosslinking with riboflavin and ultraviolet A in aim to increase the resistance of the graft used as a support for the Boston keratoprosthesis (KPro) type I against corneal melting (keratolysis or sterile necrosis).",[555],"Corneal Melting in Boston Keratoprosthesis Type I","2026-04-24",{"date":558,"type":32},"2026-04-28",{"date":560,"type":32},"2017-01-04",{"date":562,"type":21},"2028-01",{"name":38,"class":39},{"id":565,"slug":566,"hasResults":12,"nctId":567,"briefTitle":568,"officialTitle":568,"acronym":4,"eligibilityCriteria":569,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":360,"enrollmentInfo":570,"targetDuration":4,"studyType":22,"phases":572,"briefSummary":573,"conditions":574,"keywords":4,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":576,"lastUpdatePostDateStruct":577,"startDateStruct":579,"completionDateStruct":581,"leadSponsor":583,"locationsCount":116},"100453166","phase-1-topical-infliximab-in-eyes-with-penetrating-keratoplasty-100453166","NCT05180994","Topical Infliximab in Eyes With Penetrating Keratoplasty","Inclusion Criteria:\n\n* Age between 18 and 80 years;\n* First corneal transplant surgery;\n* Capable of providing informed consent;\n* Capable of administering eye medication or access to a caregiver able and willing to administer the eye medication for the patient.\n\nExclusion Criteria:\n\n* Active ocular infection;\n* Past corneal transplant (any technique);\n* Advanced glaucoma or macular disease;\n* Active or latent systemic infection (tuberculosis, histoplasmosis, coccidioidomycosis, cytomegalovirus, pneumocystis, aspergillosis or hepatitis B);\n* Malignancy diagnosed in the past 5 years (any kind);\n* Demyelinating disease;\n* History or current diabetes mellitus (controlled or uncontrolled) or heart failure (New York Heart Association class III or IV);\n* Pregnancy or breastfeeding;\n* Allergy to infliximab or to a compound of its topical formulation;\n* Significant anomaly of complete blood count or hepatic enzymes;\n* Current or anterior use of anti-TNF-α medication or other anti-inflammatory biologics.",{"count":571,"type":21},50,[203,147],"Penetrating keratoplasty is a cornea surgery involving several inflammatory complications, of which the most important is glaucoma. Researchers wish to determine whether it is safe to administer infliximab (an anti-inflammatory drug) eye drops after surgery, and whether this eye drop could prevent the occurrence of glaucoma.",[575],"Glaucoma Following Surgery","2026-04-23",{"date":578,"type":32},"2026-04-27",{"date":580,"type":32},"2022-05-01",{"date":582,"type":21},"2028-03-01",{"name":38,"class":39},{"id":585,"slug":586,"hasResults":12,"nctId":587,"briefTitle":588,"officialTitle":588,"acronym":4,"eligibilityCriteria":589,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":360,"enrollmentInfo":590,"targetDuration":4,"studyType":22,"phases":592,"briefSummary":593,"conditions":594,"keywords":598,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":576,"lastUpdatePostDateStruct":603,"startDateStruct":604,"completionDateStruct":606,"leadSponsor":608,"locationsCount":116},"100380391","the-role-of-transscleral-cyclophotocoagulation-in-patients-undergoing-a-boston-keratoprosthesis-100380391","NCT04232982","The Role of Transscleral Cyclophotocoagulation in Patients Undergoing a Boston Keratoprosthesis","Inclusion Criteria:\n\n* Adults patients\n* Able to give an informed consent\n* Capable of being followed during the study\n* Candidate for the Boston keratoprosthesis type I\n\nExclusion Criteria:\n\n* Patients younger than 18 years old or older than 80 years old\n* Unable to give an informed consent\n* Participating to another interventional glaucoma study\n* Patients who received a glaucoma surgery or procedure (glaucoma drainage device or TS-CPC treatment) 3 months before their initial visit.\n* Unable to wear a therapeutic contact lens secondary to eyelid malformation\n* Severe Ocular surface Disease with keratinization\n* Intra-ocular tumor\n* Terminal Glaucoma\n* Phthisis bulbi\n* Ocular albinism",{"count":591,"type":21},20,[24],"The Boston keratoprosthesis (KPro) is a special plastic device that is used to replace a sick cornea (transparent part of the eye, in front of the iris) in order to restore vision in patients who have failed traditional corneal transplants or have a very poor prognosis of success.\n\nGlaucoma is a chronic disease which causes optic nerve damage secondary to high pressure inside the eye and could lead to vision loss in the long term. Glaucoma is highly prevalent in patients who require a KPro and even more after their procedure.\n\nIn order to decrease the intra-ocular pressure, surgeons can use multiple eyedrops. Unfortunately, following the KPro surgery, eyedrops lose their efficiency because they are less absorbed by the eye.\n\nThe transscleral cyclophotocoagulation (TS-CPC) is a laser treatment used in advanced refractory glaucoma. This laser helps decrease the intra-ocular pressure and have a better control of the disease. There are different methods of laser transmission, including the continuous transmission (G-Probe) and the micro-pulsation method (Micopulse). Given the high prevalence of glaucoma in patients receiving a KPro, the investigators are studying the effect of giving the TS-CPC treatment prophylactically to patients before their Boston keratoprosthesis.\n\nOur hypothesis is that prophylactic TS-CPC will decrease glaucoma progression as well as the risks of developing glaucoma following the Boston keratoprosthesis .\n\nMETHOD The investigators aim to recruit twenty (20) patients who are scheduled to receive Boston KPro. Participants will be randomized into two groups: 1) Groupe 1 will receive a prophylactic treatment of transscleral cyclophotocoagulation a G-Probe. 2) Groupe 2 will receive a prophylactic treatment of transscleral cyclophotocoagulation with a micropulse transmission (MicroPulse). The patients will receive their laser treatment by a glaucoma specialist 4 to 8 weeks before their KPro surgery. One week following their laser treatment, the participants will be examined by their glaucoma specialist.\n\nFollowing their KPro surgery, patients will have a follow-up at day-1, weeks 1 and 2, months 1 and 3, then every 4 to 6 months for 5 years. Additional non-invasive glaucoma tests will be performed twice during the first 3 months following the surgery and will be repeated every 4-6 months. Visual acuity results, the visual field tests and rates of post-operative complications will be compared between the different groups.",[595,596,597],"Glaucoma","Eye Diseases","Cornea Disease",[599,600,601,602],"Boston keratoprosthesis","Transscleral cyclophotocoagulation","Micropulse transscleral cyclophotocoagulation","G-Probe Transscleral cyclophotocoagulation",{"date":578,"type":32},{"date":605,"type":32},"2020-01-30",{"date":607,"type":21},"2036-12-01",{"name":38,"class":39},{"id":610,"slug":611,"hasResults":12,"nctId":612,"briefTitle":613,"officialTitle":613,"acronym":614,"eligibilityCriteria":615,"healthyVolunteers":471,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":616,"targetDuration":4,"studyType":103,"phases":4,"briefSummary":618,"conditions":619,"keywords":624,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":576,"lastUpdatePostDateStruct":629,"startDateStruct":630,"completionDateStruct":632,"leadSponsor":634,"locationsCount":191},"100377761","proteomic-and-metabolomic-lacrimal-fingerprint-in-diverse-pathologies-of-the-ocular-surface-100377761","NCT04198740","Proteomic and Metabolomic Lacrimal Fingerprint in Diverse Pathologies of the Ocular Surface","EML-MSO","Inclusion Criteria:\n\n* Patients with healthy corneas or suffering from one of these pathologies:\n\nDry eye syndrome; Infectious keratitis and\u002For conjunctivitis; Mucous membrane pemphigoid; Allergic conjunctivitis.\n\nExclusion Criteria:\n\n* Patients younger than 18 years old;\n* Patients incapable of giving informed consent.",{"count":617,"type":21},300,"This study aims to obtain the lacrimal fingerprint for frequent pathologies of the ocular surface and establish a normative base for each of them.",[620,621,622,623],"Dry Eye Syndrome","Infectious Keratoconjunctivitis","Mucous Membrane Pemphigoid","Allergic Conjunctivitis",[625,626,627,628],"Lacrimal fingerprint","Metabolomics","Proteomics","Ocular surface",{"date":578,"type":32},{"date":631,"type":32},"2020-02-01",{"date":633,"type":21},"2035-01",{"name":38,"class":39},""]